IOVA and REPL Related Headlines
Go Back- Jefferies on Iovanace Biotherapeutics (IOVA): 'we think the pot'l risk of competition was accounted for in Street models'
- Barclays Reiterates Overweight Rating on Replimune Group (REPL), PT $17, 'We see this as a clear positive for Iovance's Amtagvi'
